Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10–20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 a...

Full description

Bibliographic Details
Main Authors: Kátia Ramos Moreira Leite, Carlos Henrique Barrios, Antônio Carlos Buzaid, Débora Gagliato, Helenice Gobbi, Fernando Soares
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Surgical and Experimental Pathology
Subjects:
Triple-negative breast cancer
Target therapy
Immunohistochemistry
PD-L1
Immune checkpoint inhibitor
Online Access:https://doi.org/10.1186/s42047-021-00092-5

Internet

https://doi.org/10.1186/s42047-021-00092-5

Similar Items